Speders S
Fortschr Med. 1993 Aug 20;111(22-23):366-8.
In an open clinical trial involving 20 patients, the question was investigated as to whether the administration of 3 x 300 mg mofebutazone daily resulted in any clinically relevant changes in blood sugar levels in diabetics treated with glibenclamide.
Fluctuations observed, both in mean and individual values, were within the range of those regularly seen in diabetics. This was shown by both weekly measurements and a comparison of daily profiles. A comparison of the daily blood sugar profile prior to and after three weeks of mofebutazone, revealed the following mean figures (+/- STD): prior to mofebutazone 12.30 hours 155.5 (+/- 23.2) mg/dl, 16.30 hours 147.2 (+/- 22.0) mg/dl; after 3 weeks of mofebutazone: 12.30 hours 162.7 (+/- 20.0) mg/dl, and 16.30 hours 151.7 (+/- 17.7) mg/dl. No side effects occurred, and no patient left the study prematurely. The laboratory parameters also studied showed no remarkable changes, either in mean values or in individual figures.
在一项涉及20名患者的开放性临床试验中，研究了每日服用3×300毫克莫比布宗是否会对接受格列本脲治疗的糖尿病患者的血糖水平产生任何临床相关变化。
观察到的平均值和个体值波动均在糖尿病患者常见波动范围内。每周测量以及每日血糖曲线比较均表明了这一点。对服用莫比布宗三周前后的每日血糖曲线进行比较，得出以下平均数据（±标准差）：服用莫比布宗前，12:30时为155.5（±23.2）毫克/分升，16:30时为147.2（±22.0）毫克/分升；服用莫比布宗三周后，12:30时为162.7（±20.0）毫克/分升，16:30时为151.7（±17.7）毫克/分升。未出现副作用，也没有患者提前退出研究。所研究的实验室参数在平均值或个体数据方面也未显示出显著变化。
